Modern possibilities of therapy for obese and overweight patients in the new reality

• Alexander S. Ametov
• Mayya A. Garieva
• Kamilya R. Ozdemirova

Abstract

Obesity is one of the most common diseases in economically developed countries, leading to the development of type 2 diabetes mellitus and cardiovascular diseases. The central place in the treatment of obesity is occupied by property selected drug therapy. Evidence from this clinical case the efficacy of treatment for overweight and obese patients with a fixed combination of sibutramine and metformin is shown, which demonstrates the feasibility of using Reduxin forte as well as a logical pharmacotherapy option when canceling liraglutide.

Keywords:metabolic health; obesity; sibutramine; metformin; Reduxin forte

References

1. Scherer P.E. The many secret lives of adipocytes: implications for diabetes. Diabetologia. 2019; 62 (2): 223–32. DOI: https://doi.org/10.1007/s00125-018-4777-x

2. Dedov I.I., Romantsova T.I., Shestakova M.V. Rational approach to the treatment of patients with DM2 and obesity: results of the All-Russian observation program «AURORA». Ozhirenie i metabolism [Obesity and Metabolism]. 2018; 15 (4): 48–58. DOI: https://doi.org/10.14341/omet10076 (in Russian)

3. Pyanykh O.P., Gusenbekova D.G., Ametov A.S. Advantages of long-term management of metabolic health in patients with obesity and early disorders of carbohydrate metabolism. Endokrinologiya: novosti, mneniya, obuchenie [Endocrinology: News, Opinions, Training]. 2020; 9 (2): 40–8. DOI: https://doi.org/10.33029/2304-9529-2020-9-2-40-48 (in Russian)

4. URL: www.roszdravnadzor.gov.ru

5. Ametov A.S. Report on the SPRING program. Effective treatment of obesity is the way to fight the epidemic of diabetes mellitus. Endokrinologiya: novosti, mneniya, obuchenie [Endocrinology: News, Opinions, Training]. 2013; 2 (3): 12–6. (in Russian)

6. Riaz H., Khan M.S., Siddiqi T.J., et al. Association between obesity and cardiovascular outcomes: a systematic review and meta-analysis of mendelian randomization studies. JAMA Netw Open. 2018; 1 (7): e183788. DOI: https://doi.org/10.1001/jamanetworkopen.2018.3788

7. Ametov A.S., P’yanykh O.P., Nevol’nikova A.O. Modern possibilities of metabolic health management in patients with obesity and carbohydrate metabolism disorders. Endokrinologiya: novosti, mneniya, obuchenie [Endocrinology: News, Opinions, Training]. 2020; 9 (1): 17–26. (in Russian)

8. Demidova T.Yu., Izmaylova M.Ya., Ushakova S.E., Zaslavskaya K.Ya., Odegova A.A., Popova V.V., et al. Evaluation of the effectiveness of weight loss and the safety of the use of sibutramine-containing drugs in patients with alimentary obesity. Farmatsiya i farmakologiya [Pharmacy and Pharmacology]. 2022; 10 (3): 289–304. DOI: https://doi.org/10.19163/2307-9266-2022-10-3-289-304 (in Russian)

9. Matveev G.A., Golikova T.I., Vasil’eva A.A., Vasil’eva E.Yu., Babenko A.Yu., Shlyakhto E.V. Comparison of effects of obesity therapy with liraglutide and sibutramine. Ozhirenie i metabolism [Obesity and Metabolism]. 2021; 18 (2): 218–28. DOI: https://doi.org/10.14341/omet12498 (in Russian)

10. Demidova T. Yu. Reduxin is a new means of solving old problems! Diabet. Obraz Zhizni [Diabetes. Lifestyle]. 2007; (4): 4–7. (in Russian)

11. Tereshchenko I.V. Endocrine function of adipose tissue. Problems of obesity treatment. Klinicheskaya meditsina [Clinical Medicine]. 2002; 80 (7): 9–14. (in Russian)

12. Romantsova T.I. Sibutramine: efficacy and safety of use in routine clinical practice. Ozhirenie i metabolism [Obesity and Metabolism]. 2015; 12 (3): 18–24. (in Russian)

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)